4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies

4D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for annualized standard-of-care injections in patients with wet age-related macular degeneration.